Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Meclofenoxate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 known ✓ | Q9Y5N1 | 1/20 | 0.60 |
| ▸ | GAA known ✓ | P10253 | 2/20 | 0.52 |
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.97 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.97 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.97 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.76 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | ESRRG | P62508 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Meclofenoxate SCHEMBL147339 | 0.98 | CYP1A2 (1.00) | BLMPMP22CYP1A2CYP3A4CYP2C19 | |
| Meclofenoxate SCHEMBL28363047 | 0.97 | CYP1A2 (0.97) | BLMPMP22CYP1A2CYP3A4CYP2C19 | |
| Meclofenoxate SCHEMBL1172142 | 0.96 | CYP1A2 (0.94) | BLMPMP22CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL12742257 | 0.85 | SMN1; SMN2 (0.97) | BLMPMP22CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL31122986 | 0.83 | SMN1; SMN2 (0.73) | BLMPMP22CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL28252143 | 0.81 | CYP1A2 (0.70) | BLMPMP22CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL6598625 | 0.81 | HRH3 (0.69) | BLMPMP22CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL21384542 | 0.80 | CYP1A2 (0.68) | BLMPMP22CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL25391970 | 0.79 | TDP1 (0.70) | BLMPMP22CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL6599620 | 0.79 | HRH3 (0.67) | BLMPMP22CYP1A2CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1416 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025128607-A1 | METHOD AND APPARATUS FOR HIGH-THROUGHPUT TRANSFECTION OF CELLS USING ELECTROPORATION | TRIPLE RING TECHNOLOGIES, INC. (US) | 2025-06-19 | — | — | WO | claimed |
| US-20250168765-A1 | JOINTLY OPTIMIZE NETWORK AND DEVICE POWER SAVING | LENOVO (SINGAPORE) PTE. LIMITED (SG) | 2025-05-22 | — | — | US | claimed |
| CN-119033649-B | Cell active peptide composition with tightening and anti-aging effects and preparation method and application thereof | 珠海金肽生物科技有限公司 | 2025-04-29 | — | — | CN | claimed |
| WO-2025052369-A1 | JOINTLY OPTIMIZE NETWORK AND DEVICE POWER SAVING | LENOVO (SINGAPORE) PTE. LTD. (SG) | 2025-03-13 | — | — | WO | claimed |
| CN-119485400-A | Communication method, device, storage medium, and product | 中国移动紫金(江苏)创新研究院有限公司 | 2025-02-18 | — | — | CN | claimed |
| CN-119258242-A | Intranasal delivery of fluorescent markers | UCL商业有限公司 | 2025-01-07 | — | — | CN | claimed |
| CN-119074893-A | Cell active peptide composition for resisting acne and regulating skin microecology, preparation method thereof and application thereof in medicine and cosmetology | 珠海金肽生物科技有限公司 | 2024-12-06 | — | — | CN | claimed |
| CN-119033649-A | Cell active peptide composition with tightening and anti-aging effects and preparation method and application thereof | 珠海金肽生物科技有限公司 | 2024-11-29 | — | — | CN | claimed |
| CN-118225911-A | Method for detecting impurities in meclofenoxate hydrochloride | 江苏汉斯通药业有限公司 | 2024-06-21 | — | — | CN | claimed |
| CN-117330648-A | Method for measuring residual solvent in meclofenoxate hydrochloride by capillary gas chromatography | 江苏汉斯通药业有限公司 | 2024-01-02 | — | — | CN | claimed |
| EP-1334716-A1 | MEDICINAL COMPOSITIONS QUICKLY DISINTEGRATING IN THE ORAL CAVITY AND PROCESS FOR PRODUCING THE SAME | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-08-13 | — | — | EP | claimed |
| CN-1074933-C | Anti-stress, anti-impairment and anti-aging drug and process for manufacturing thereof | RIGA D (RO) | 2001-11-21 | — | — | CN | claimed |
| US-6174890-B1 | A SYNERGISTIC BIOLOGICAL, NEUROMETABOLIC AND CELLTROPHIC COMPOSITION COMPRISING ANTIOXIDATIVE AND -CATABOLIC STRESS (METHIONINE),-ANABOLIC DRUGS, VASODILATIVE AND NORMO-LIPIDEMIC DRUGS (NICOTINIC ACID), ENERGOACTIVE AND ANTITOXIC | RIGA DAN (RO) | 2001-01-16 | — | — | US | claimed |
| EP-0804239-B1 | ANTI-STRESS, ANTI-IMPAIRMENT AND ANTI-AGING DRUG AND PROCESS FOR MANUFACTURING THEREOF | RIGA DAN (RO) | 1999-09-15 | — | — | EP | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| US-5700410-A | Method of manufacturing wax matrices | NIPPON SHINYAKU CO., LTD. (JP) | 1997-12-23 | — | — | US | claimed |
| EP-0804239-A1 | ANTI-STRESS, ANTI-IMPAIRMENT AND ANTI-AGING DRUG AND PROCESS FOR MANUFACTURING THEREOF | Riga, Dan (RO) | 1997-11-05 | — | — | EP | claimed |
| EP-0580860-B1 | METHOD OF MANUFACTURING SOLID DISPERSION | NIPPON SHINYAKU CO LTD (JP) | 1997-10-22 | — | — | EP | claimed |
| CN-1156410-A | Anti-stress, anti-injury and anti-aging medicine and production method thereof | RIGA D (RO) | 1997-08-06 | — | — | CN | claimed |
| WO-1995033486-A1 | ANTI-STRESS, ANTI-IMPAIRMENT AND ANTI-AGING DRUG AND PROCESS FOR MANUFACTURING THEREOF | RIGA DAN (RO) | 1995-12-14 | — | — | WO | claimed |